Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Shares Outstanding (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Shares Outstanding for 3 consecutive years, with $56.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.97% to $56.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Dec 2025, up 1.97% year-over-year, with the annual reading at $56.4 million for FY2025, 1.97% up from the prior year.
  • Shares Outstanding hit $56.4 million in Q4 2025 for Connect Biopharma Holdings, up from $55.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $56.4 million in Q4 2025 to a low of $55.1 million in Q4 2023.
  • Historically, Shares Outstanding has averaged $55.5 million across 3 years, with a median of $55.3 million in 2024.
  • Biggest five-year swings in Shares Outstanding: increased 0.45% in 2024 and later rose 1.97% in 2025.
  • Year by year, Shares Outstanding stood at $55.1 million in 2023, then grew by 0.45% to $55.3 million in 2024, then increased by 1.97% to $56.4 million in 2025.
  • Business Quant data shows Shares Outstanding for CNTB at $56.4 million in Q4 2025, $55.8 million in Q3 2025, and $55.6 million in Q2 2025.